Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of HeartWare International Inc. (NASDAQ:HTWR) investors concerning whether the company’s officers and board of directors violated the federal securities laws.

On October 13, 2015, HeartWare announced that the company may not reinitiate enrollment in its MVAD heart pump clinical trials in November 2015, as previously announced. Following the announcement of this news, HeartWare stock plunged $8.82 per share, or 20%, to a close at $35.21 per share on October 13, 2015.

If you purchased HeartWare securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact J. Brandon Walker, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information, please go to www.bespc.com.

Bragar Eagel & Squire, P.C.J. Brandon Walker, Esq., 212-355-4648investigations@bespc.com

Heartware International, Inc. (MM) (NASDAQ:HTWR)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Heartware International, Inc. (MM) Charts.
Heartware International, Inc. (MM) (NASDAQ:HTWR)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Heartware International, Inc. (MM) Charts.